Pounder R
Royal Free Hospital School of Medicine, Academic Department of Medicine, London, United Kingdom.
Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):626-31. doi: 10.1016/s0016-5085(89)80058-7.
Peptic ulcer hemorrhage or perforation occur commonly in patients with hitherto silent ulceration, particularly in the elderly or in those taking nonsteroidal antiinflammatory drugs. The majority of patients dying from peptic ulceration have no symptoms of ulcer disease until the presentation of their final, fatal illness. There is a need for more studies investigating the early symptoms of the fatal ulcer disease, the effects of therapies that may prevent fatalities, and the management of potentially lethal ulcer disease upon clinical presentation. Silent ulceration also occurs in patients after successful healing with medical treatment, and the apparent point prevalence of silent ulceration (in the framework of a clinical trial) is critically dependent on the frequency of repeat endoscopic examination and the treatment modality. Maintenance treatment with H2-receptor antagonists appears to some extent to decrease the frequency of asymptomatic ulcers, but more interestingly to halt the progression of asymptomatic ulcers toward symptomatic or complicated ulceration, although more careful studies in comparison with other modalities are needed.
消化性溃疡出血或穿孔常见于既往无症状性溃疡的患者,尤其是老年人或服用非甾体类抗炎药的患者。大多数死于消化性溃疡的患者在出现最终致命疾病之前并无溃疡病症状。需要开展更多研究来调查致命性溃疡病的早期症状、可能预防死亡的治疗方法的效果以及临床出现潜在致命性溃疡病时的处理。无症状性溃疡也见于经药物治疗成功愈合后的患者,而且(在临床试验框架内)无症状性溃疡的表观现患率严重取决于重复内镜检查的频率和治疗方式。H2受体拮抗剂维持治疗在一定程度上似乎可降低无症状性溃疡的发生率,但更有意思的是可阻止无症状性溃疡向有症状或复杂性溃疡发展,不过与其他治疗方式相比还需要更严谨的研究。